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associated with pathogenesis in stem cells. Relative quantification mass spectrometry was employed to identify
pathways affected by Tel/PDGFRβ, an oncogene associated with myeloproliferative neoplasia (MPN). Its effects on
over 1800 proteins were quantified with high confidence. Of those up-regulated by Tel/PDGFRβ several were
involved in the interferon gamma (IFNγ) response. To validate these observations we employed embryonic and
myeloid stem cells models which revealed Tel/PDGFRβ-induced STAT1 up-regulation and activation was responsible
for modulating the interferon response. A STAT1 target highly up-regulated was ICSBP, a transcriptional regulator of
myeloid and eosinophilic differentiation. ICSBP interacts with CBP/p300 and Ets transcription factors, to promote
transcription of additional genes, including the Egr family, key regulators of myelopoiesis. These interferon responses
were recapitulated using IFNγ stimulation of stem cells. Thus Tel/PDGFRβ induces aberrant IFN signaling and
downstream targets, which may ultimately impact the hematopoietic transcriptional factor network to bias
myelomonocytic differentiation in this MPN.
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doi:10.1016/j.scr.2010.08.001IntroductionMyeloproliferative neoplasms (MPN) share the common
characteristics of being stem cell-derived clonal diseases
with activated signal transduction pathways due to mutation
of a tyrosine kinase, often involving an acquired chromo-
somal translocation (Tefferi and Vardiman, 2008; Shtivelman.
227Leukaemic oncogene Tel/PDGFRβ in stem cellset al., 1985; Tefferi and Gilliland, 2007). A subset of these
disorders involves constitutively active translocations of the
platelet-derived growth factor receptor-β (PDGFRβ) (Golub
et al., 1994; Carroll et al., 1996; Tomasson et al., 2000). One
such translocation, t(5:12)(q33;p13), fuses Tel (an Ets-
related transcription factor) at 12p13 to the PDGFRβ gene
at 5q33, producing the chimeric protein, Tel/PDGFRβ (Golub
et al., 1994). This translocation results in patients develop-
ing a MPN with myelomonocytic accumulation often associ-
ated with eosinophilia. Expression of Tel/PDGFRβ in a
murine bone marrow transplantation model induces a
myeloproliferative disease that closely resembles the clin-
ical symptoms of MPN in humans, implicating Tel/PDGFRβ as
the pathological oncoprotein in this disorder (Tomasson
et al., 2000). Tel/PDGFRβ expression in cell lines causes
activation of several signaling molecules important for
mitogenesis, with STAT5 and ERK activation making an
important contribution to this process of transformation
(Golub et al., 1994; Carroll et al., 1996; Tomasson et al.,
2000; Jousset et al., 1997; Wilbanks et al., 2000; Wheadon
and Welham, 2003; Cain et al., 2007; Valgeirsdottir et al.,
1998; Dobbin et al., 2009).
However, the process of transformation is more complex
than activation of canonical signaling pathways. We have
previously shown using a proteomic approach that six distinct
leukemogenic kinases affect the expression of a plethora of
proteins in distinctive fashion (Pierce et al., 2008). This
discovery phase requires further steps involving verification
and validation steps after global analysis. This can establish a
detailed network of the biological pathways altered during
the initiating steps involved in leukemic transformation
(Griffiths et al., 2007; Cristea et al., 2004).
In previous studies we have generated and characterized
a myeloid stem cell model (Unwin et al., 2005) and shown
that Tel/PDGFRβ promotes early myeloid differentiation but
suppresses maturation of mature granulocytes. Further work
using an embryonic stem (ES) cell model with hematopoietic
potential demonstrated that Tetracycline (Tet)-regulated
expression of Tel/PDGFRβ prevents ES cell self-renewal and
drives myelopoiesis via aberrant STAT5 and MAP kinase
signaling (Dobbin et al., 2008, 2009). Validation of this
approach comes from the work of Cain et al., who
demonstrated a role for STAT5 in Tel/PDGFRβ-mediated
myeloproliferation (Cain et al., 2007). Proteomics offers the
opportunity to dissect the pathways associated with leuke-
mic transformation with relatively high sensitivity as pep-
tides can be detected, sequenced, and relatively quantified
using tandem mass spectrometry (Griffiths et al., 2007). In
this study we have utilized such a high throughput
proteomics approach to investigate the mechanisms involved
in oncogenic transformation by Tel/PDGFRβ. In total 47
proteins were shown to change their expression following
Tel/PDGFRβ induction. From this hypothesis generation
approach we identified several proteins directly involved in
IFNγ signaling or which can be altered as a consequence of
IFNγ signaling. We then extended our analysis with hypoth-
esis driven research to show that Tel/PDGFRβ-mediated
activation of the STAT1 pathway induces sustained, aberrant
IFNγ signaling, altering the hematopoietic transcriptional
network contributing to enhanced myeloproliferation along
the myelomonocytic route. Stimulation of primitive stem
cells and more committed myeloid progenitors revealed thatstem cells can respond to IFNγ, indicating that the IFNγ
response plays an important role in controlling myelopoiesis
early on during differentiation.
Results
Identification of Tel/PDGFRβ-induced alterations in
the proteome
Tel/PDGFRβ (TP)-transfected ES cells were cultured for 24 h in
the presence of Tet to prevent Tel/PDGFRβ expression (TP–,
control sample) or absence of Tet (TP+, test sample) to induce
maximal oncoprotein expression and tyrosine phosphorylation
of cellular proteins (Fig. 1A). These cells were then taken for
relative quantification mass spectrometry (MS) analysis to
determine novel means for cellular transformation, as outlined
in Supplementary Fig. 1. This approach involved the use of two
rounds of 4-channel isobaric tagging for relative quantification
of tryptic peptides and thereafter proteins, allowing four
independent sample sets (TP+:TP–) to be analyzed in total. The
internal controls for each of the four Plex iTRAQ experiments
were the two independent samples cultured with tetracycline
to prevent Tel/PDGFRβ expression (TP–). From the two iTRAQ
runs a total of 1320 and 1576 proteins were identified at false
discovery rates of 0.5543 and 0.1706%, respectively. Relative
quantification was performed on a final combined, curated
protein list of 1812proteinswith the cutoff values for significant
change being applied, namely ≥1.2 and ≤0.8 (Supplementary
Table 2) (Pierce et al., 2008; Unwin et al., 2005), indicating
good penetration of approximately 20% of the total cellular
proteome. Due to the low abundance of Tel/PDGFRβ and the
complexity of global proteomic samples, Tel/PDGFRβ was not
identified in the proteomic screen. However its expression and
activation were clearly demonstrated using Western blot
analysis prior to the proteomic analysis (Fig. 1A).
In both experiments the labeling efficiency was N98%,
determined by comparing the total number of potential
reactive sites (i.e., N-termini and lysine side chains) with the
iTRAQ modification present. Fig. 1B demonstrates the
robustness of the iTRAQ technique with the ratio of the
majority of proteins lying between the expressional cutoffs
of 0.8 and 1.2 for both the TP– cells vs TP– cells (control) and
the TP+cells vs TP– cells (test). With the average standard
ratio for the TP+cells versus TP– cells 1.019±0.015, n=4,
and TP– cells versus TP– cells 1.015±0.03, n=2. Functional
analysis and characterisation of the total identified protein
set showed excellent coverage of the whole proteome
(Fig. 1D and Supplementary Table 2). On induction of TP
(and comparison thereafter of TP+vs TP–) 47 proteins were
identified as being significantly differentially expressed (12
were down-regulated and 35 up-regulated) (Fig. 1C and
Supplementary Table 3). Characterisation of these indicated
that approximately 25.5% were involved in cell motility/
cytoskeleton, 6.4% nucleic acid metabolism, 14.9% tran-
scription, 6.4% protein biosynthesis, 10.6% oxidative phos-
phorylation, 10.6% proteasome, 8.5% IFNγ response, 2.1%
signal transduction. One of the most significant changes seen
was in the interferon-induced proteins (0.2% of proteins
identified in the total proteome, compared to 8.5% of the
proteins differentially expressed by Tel/PDGFRβ) (Fig. 1D
and Supplementary Table 4).
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The most highly up-regulated proteins by Tel/PDGFRβ were
involved in IFNγ signaling, namely IFNγ GTPases, GBP1,
GBP2, and transmembrane protein 3. Two immunoprotea-
some components, MECL-1 and PA28α, were also identified
as being up-regulated by expression of Tel/PDGFRβ. TheseB
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Figure 1 Proteomic screen to identify proteins altered by Tel/PDGF
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Figure 1 (continued).
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230 E. Dobbin et al.The discovery proteomics data inferred a potential role
for the IFNγ pathway in transformation mediated by an
oncogene associated with monocytic lineage. Given the
important role IFNγ signaling plays in HSC homeostasis,
myeloid differentiation, and activation of mature macro-
phages (Baldridge et al., 2010; Schroder et al., 2004;
Schindler and Plumlee, 2008), this is potentially an impor-
tant mechanism in the pathogenesis of this MPN. To validate
this we examined proteomic and transcriptome data
generated using myeloid cells to overexpress Tel/PDGFRβ
(Pierce et al., 2008); this also inferred deregulation of the
interferon response by this oncogene (Supplementary Fig. 2).
Our hypothesis emanating from these systematic analyses
was that this pathway may be chronically affected at several
different levels by Tel/PDGFRβ. That this occurs in two
different cellular backgrounds emphasizes its potential
importance. In order to verify whether the IFNγ response
was important in regulating primitive stem cells and myeloid
progenitors we utilized both the ES and the FDCP-Mix
hematopoietic stem cell models to overexpress Tel/PDGFRβ
and to examine the effects of IFNγ stimulation on primitive
stem cells and during myelopoiesis.STAT1 signaling and downstream components of the
IFNγ response induced by Tel/PDGFRβ in ES cells
Activation of STAT1 is a vital component of IFNγ signaling
(Schindler and Plumlee, 2008). Western blot analysis
(Fig. 2A, i) indicates that following Tel/PDGFRβ induction,
STAT1 was rapidly up-regulated and became phosphorylated
on both tyrosine (Y701) and serine (S727) residues, indicative
of activation. As previously described Tel/PDGFRβ also
activated p38 and ERK kinases (Dobbin et al., 2009) which
phosphorylate STAT family members on serine residues
(Schroder et al., 2004; Schindler and Plumlee, 2008). Using
concentrations of U0126 and SB202190 previously deter-
mined to inhibit pERK and pp38 and have no detrimental
effects on parental E14Tga cells (Dobbin et al., 2009; Paling
et al., 2004) we inhibited Tel/PDGFRβ-mediated activation
of these pathways. Inhibiting p38 reduced the level of STAT1
serine phosphorylation by 2.25±0.36-fold, n=3 (10 μM
SB202190) and 4.19±0.22-fold, n=3 (25 μM SB202190)
whereas inhibition of MEK activation had no effect,
indicating a role for p38 in Tel/PDGFRβ-induced STAT1
serine phosphorylation (Fig. 2A, ii). These results imply that
the increase in IFNγ response proteins identified in the
proteomic screen was likely to be mediated through Tel/
PDGFRβ activation of STAT1 signaling.
Next we confirmed that the GTPases and GBPs identified
in the proteomic screen were up-regulated by Tel/PDGFRβ
at the transcriptional level in ES cells (Fig. 2B, i). We then
ascertained whether other downstream targets of the IFNγ
response were induced by Tel/PDGFRβ. IFN transcription is
regulated by STAT1 inducing interferon response factors
(IRF). Analysis of mRNA levels showed IRF-4 and ICSBP (IRF-8)
are up-regulated following Tel/PDGFRβ expression in ES
cells, IRF-9 increased slightly, whereas IRF-1 and IRF-2 did
not alter (Fig. 2B, ii). The IRF family can either initiate or
suppress transcription depending on their interaction with
other transcriptional regulators, including STATs, histone
deacetylases (HDACs), and the Ets transcription factors. Wetherefore examined the expression of several target genes
and found that HDAC3, STAT2, C/EBPε, GATA1, and GATA2
were up-regulated, HDAC2 and Tel did not alter, and HDAC9
was down-regulated (Fig. 2B, iii). One of the largest changes
observed was ICSBP, a key regulator of the IFNγ response and
of monocytic differentiation. Western blot analysis con-
firmed that Tel/PDGFRβ was also up-regulating ICSBP at the
protein level (Fig. 2C, i). ICSBP directly controls genes
involved in monocytic differentiation and survival. Therefore
we investigated a panel of these genes. Fig. 2C, ii, indicates
increased transcription of Egr1 and Egr2, no alteration in PML
and Bcl-2, and a slight decrease in NF1, following Tel/
PDGFRβ expression. Quantitative PCR analysis was also
performed to confirm the up-regulation of ICSBP, C/EBPε,
Egr1, and Egr2 expression induced by Tel/PDGFRβ compared
to control cells (Figs. 2B, iv, and 2C iii). These results
indicate that the oncogene Tel/PDGFRβ induces IFNγ
signaling via STAT1 activation which subsequently alters
the transcriptional flux to cause an aberrant interferon
response.
Inhibition of the protein tyrosine kinase activity of
Tel/PDGFRβ prevents STAT1 expression and signaling
Next we examined whether inhibition of the tyrosine kinase
activity of Tel/PDGFRβ could prevent STAT1 up-regulation
and activation. Cells were induced to express Tel/PDGFRβ
for 24 h in the presence or absence of imatinib mesylate or a
specific PDGFRβ protein kinase inhibitor. Both inhibitors
reduced overall tyrosine phosphorylation of cellular proteins
(Dobbin et al., 2009) and prevented STAT1 up-regulation and
activation (Fig. 2D, i). To investigate whether the tyrosine
kinase inhibitors could also prevent Tel/PDGFRβ-mediated
downstream IFNγ responses, we analyzed several of the
genes shown to be deregulated by Tel/PDGFRβ. Both
tyrosine kinase inhibitors were able to reduce the levels of
ICSBP, IRF-9, HDAC3, GBP2, and the Egr family of genes
(Fig. 2D, ii). These data demonstrate that the tyrosine kinase
activity of Tel/PDGFRβ results in downstream signals that
induce STAT1 up-regulation and activation leading to
induction of the IFNγ response.
Negative regulation of the IFNγ response
Several proteins have been shown to negatively regulate
STAT signaling, including the SOCS and PIAS family of
proteins (Krebs and Hilton, 2001; Greenhalgh and Hilton,
2001). RT-PCR was carried out to measure levels of SOCS1,
SOCS2, SOCS3, PIAS1, PIAS2, and PIAS3 following Tel/
PDGFRβ induction. No alterations in the PIAS family were
observed; however, higher levels of SOCS1 and SOCS3 were
seen (Fig. 2E, i), which could be reversed by the protein
tyrosine kinase inhibitors (Fig. 2E, ii), supporting previous
reports that SOCS1 and SOCS3 are induced by STAT1 and can
negatively regulate JAK/STAT signaling, via the blockade of
JAK tyrosine kinase activity (Krebs and Hilton, 2001; Kovarik
et al., 1999). However, Tel/PDGFRβ has the capacity to
activate STAT signaling in a JAK-independent fashion
(Wilbanks et al., 2000), making this feedback mechanism
unlikely to be effective. Thus we explored another negative
regulator of the IFNγ response, endogenous Tel, which can
231Leukaemic oncogene Tel/PDGFRβ in stem cellsinteract with ICSBP and HDAC3 to repress ISRE-mediated
transcription. RT-PCR indicated that Tel transcription did
not alter, whereas HDAC3 was up-regulated following Tel/
PDGFRβ induction (Fig. 2B, iii), suggesting that this negative- +   - + Tel/PDGFRβ
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232 E. Dobbin et al.et al., 2004; Arai et al., 2002). Since Tel/PDGFRβ activates
both MAP kinases (Fig. 2A, i) we investigated the localisation
of Tel following Tel/PDGFRβ induction. Our results indicated
that higher levels of the 50-kDa Tel protein were detected
48 h following Tel/PDGFRβ expression, which was located in
the cytoplasmic fraction whereas the 56-kDa Tel protein was
detected in the nuclear fractions (Fig. 2E, iii and iv). In order
to test the ability of endogenous Tel to suppress transcription
we examined one of its target genes Id1. Fig. 2E, v,
demonstrates that Id1 was up-regulated following Tel/
PDGFRβ expression, signifying that Tel was unable to
suppress its transcription. These results indicate that
although strong negative feedback mechanisms are induced
in cells expressing Tel/PDGFRβ, these are unable to
effectively switch off Tel/PDGFRβ-induced IFNγ signaling,
thus contributing to the sustained IFNγ response.Tel/PDGFRβ induces the IFNγ response in
hematopoietic cells
In order to validate whether deregulation of the IFNγ
response was a common phenomena induced by this
oncogene we investigated downstream components of IFNγsignaling in the BaF3 hematopoietic cell line. Expressing Tel/
PDGFRβ up-regulates and activates STAT1 as previously
described (Wilbanks et al., 2000), and increased transcrip-
tion of GBP1 and 2, GTPase 1 and 2, IRF-4, IRF-9, STAT2,
SOCS1, and 3 (Supplementary Fig. 3), confirming that this
oncogene affects the IFNγ response in hematopoietic cells as
well as pluripotent stem cells. However, ICSBP and Egr1,
transcriptionaly regulated by ICSBP, were absent, with ICSBP
only detected at very low levels following 48 h Tel/PDGFRβ
expression, reflecting the fact that these are monocytic
specific genes and BaF3 are a pro-B cell line.Tel/PDGFRβpromotesmyelomonocytic differentiation
and suppresses neutrophilic differentiation
To ascertain the effects of expressing Tel/PDGFRβ on
myelomonocytic and neutrophilic differentiation we
employed a myeloid stem cell model. Fig. 3A, i, clearly
demonstrates that FDCP-Mix cells expressing the oncogene
have a more differentiated phenotype than control cells with
more late myeloid progenitors and terminally differentiated
cells observed in the cultures at Day 0. However when
directed to undergo myelomonocytic differentiation Tel/
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233Leukaemic oncogene Tel/PDGFRβ in stem cellsPDGFRβ suppressed differentiation compared to control cells
(Fig. 3A, ii). This was more apparent when cells were
directed to undergo neutrophilic commitment with blast and
early progenitors still present following 7 days differentia-
tion in the Tel/PDGFRβ-expressing cultures. In addition the
oncogene biased cells to undergo myelomonocytic differen-
tiation when directed to undergo neutrophilic differentia-
tion (Fig. 3A, iii). This was reflected in the hematopoietic
transcription factor pattern (Fig. 3B, ii), with Tel/PDGFRβ-
expressing cells having high levels of GATA1, C/EBPε, and
VDR whereas induction of granulocytic genes GFi and G-CSF-
R were suppressed during neutrophilic differentiation.Tel/PDGFRβ up-regulates STAT1 and the IFNγ response
during myeloid commitment
To establish whether STAT1 was activated throughout the
differentiation process, Western blotting analysis was
carried out. Fig. 3C clearly demonstrates that the oncogene
was active throughout both myelomonocytic and neutrophil-ic differentiation and STAT1 was up-regulated and phos-
phorylated on both Y701 and S727 residues. In addition other
downstream transcription factors involved in the IFNγ
response were up-regulated by the oncogene, including
GBP1 and 2, GTPase 1 and 2, IRF-4, ICSBP, STAT2, and HDAC9
(Figs. 3D and 3E, ii). ICSBP transcription was high in FDCP-Mix
cells, which was increased by Tel/PDGFRβ throughout both
the myelomonocytic and neutrophilic differentiation
(Fig. 3D, iii). This was reflected by higher Egr1 and 2 levels
during myelomonocytic differentiation (Fig. 3E, i). Tel/
PDGFRβ also induced the negative regulators SOCS1 and 3
which inhibit STAT1 signaling. Although no alterations in Tel
transcription were observed, Id1 levels were higher in the
oncogene-expressing cells, suggesting that its negative
regulatory role was ineffective in cells expressing the
oncogene (Fig. 3E, ii).
IFNγ up-regulates the IFNγ response in ES and
FDCP-Mix cells
In order to identify the downstream effects mediated by IFNγ
alone as apposed to the combined signals emanating from Tel/
PDGFRβ, we carried out a series of short-term stimulations on
the two stem cell models. Initially we investigated whether
STAT1 could be induced in ES cells following culture with IFNγ.
Fig. 4A indicates that ES cells do not normally express STAT1;
however, in the presence of IFNγ, STAT1 levels gradually
increased and became phosphorylated on both Y701 and S727
residues. In addition GBP1 and 2, GTPase1 and 2, IRF-2, 4, 9,
ICSBP, Egr1, C/EBPε, and SOCS1 and 3 were all up-regulated
following IFNγ stimulation (Figs. 4B and 4C) whereas no
alterations in STAT2, HDAC, Bcl-2, NF1, and Egr2 were
observed. Short-term stimulation of FDCP-Mix cells with IFNγ
showed results very similar to those observed for the ES cells,
with the only exception being up-regulation of IRF-1, STAT2,
andHDAC9 and no expression of IRF-4 in themyeloid stem cells
(Figs. 5A and 5B). Interestingly the only hematopoietic specific
transcription factors tested that were up-regulated by IFNγ in
both stem cell models were C/EBPε and Egr1, indicating that
GATA1 and 2 are regulated through additional signals
downstream of Tel/PDGFRβ either in combination or indepen-
dently of the IFNγ response.
Effects of IFNγ stimulation on myelopoiesis
Previous reports have shown that IFNγ is important for
monocytic differentiation as well as activation of mature
macrophages (Schroder et al., 2004; Schindler and Plumlee,
2008). Furthermore we have shown that enriched bipotent
granulocyte/macrophage progenitor cells are influenced to
develop along the macrophage lineage by addition of IFNγ (Kan
et al., 1991). We therefore investigated the effects of IFNγ
stimulation onmyelomonocytic and neutrophilic differentiation
of FDCP-Mix cells. Supplementation with IFNγ resulted in cells
differentiating faster than the control cultures (Fig. 6A, i). This
wasmore apparent at Day 4 of differentiationwithmoremature
cells observed in the myelomonocytic cultures and less in the
neutrophilic cultures (Fig. 6A, ii and iii). IFNγ like Tel/PDGFRβ
was also able to favor myelomonocytic differentiation in the
cultures induced to undergo neutrophilic differentiation, which
was reflected in the hematopoietic transcription factor
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Figure 4 IFNγ up-regulates STAT1 and the IFNγ response in ES cells. (A) IFNγ induces STAT1 expression and activation in ES cells.
Parental ES cells were cultured +/– IFN for 24, 48, and 72 h; representative gel images are shown for each experiment, n=3. (A) Cell
extracts immunoblotted for STAT1, pSTAT1, with SHP-2 used as a loading control. (B) RT-PCR analysis of genes involved in the IFNγ
response following IFNγ stimulation (i and ii). (C) Analysis of additional downstream transcription factors involved in the IFN response (i).
Changes in ICSBP, C/EBPε, Egr1, and Egr2 levels were confirmed by quantitative PCR; * Pb0.05, # Pb0.005 by paired Students t test, n=3
(ii).
235Leukaemic oncogene Tel/PDGFRβ in stem cellsexpression pattern with lower levels of C/EBPε, PU.1, VDR, GFi,
and G-CSF-R observed following IFNγ stimulation (Fig. 6B).
Analysis of the IFNγ response indicates that STAT1 was up-Figure 3 Tel/PDGFRβ promotes myelomonocytic differentiation and
differentiation as assessed by culturing control and Tel/PDGFRβ-transfec
differentiation over 7 days. (A) Morphology was determined on Days 0,
b10% in all cases with 250 cells counted per condition for each experim
promonocytes (i). Tel/PDGFRβ suppresses monocytic differentiation,
neutrophilic differentiation, * Pb0.05, # Pb0.005, n=3 (iii), by paired St
genes following Tel/PDGFRβ expression, during monocytic (i) and neutro
antibodies against phosphotyrosine, STAT1, pSTAT1, PDGFRβ, ICSBP,
downstream transcription factors involved in the IFN response (i and ii
quantitative PCR; * Pb0.05 by paired Students t test, n=3. (E) RT-PCR o
shown for each experiment, n=3.regulated and activated following IFNγ stimulation, leading to
ICSBP expression (Fig. 6C). Other components of the IFNγ
response including GBP1 and 2, GTPase1 and 2, IRF-1, 2, 9,suppresses neutrophilic differentiation. Effects of Tel/PDGFRβ on
ted FDCP-Mix cells in cytokines to inducemonocytic or neutrophilic
4, and 7. Results shown are the mean of three experiments; SE was
ent. Late progenitors indicate metamyelocytes, myelocytes, and
# Pb0.005, n=3 (ii), and promotes monocyte formation during
udents t test. (B) RT-PCR analysis of hematopoietic and granulocytic
philic (ii) differentiation. (C) Protein extracts immunoblotted using
with GAPDH used as a loading control. (D) RT-PCR analysis of
), n=3. (iii) Changes in ICSBP levels seen by RT-PCR, confirmed by
f genes regulated by ICSBP (i and ii). Representative gel images are
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Figure 5 IFNγ induces the IFNγ response in FDCP-Mix cells. (A) RT-PCR analysis of mRNA levels following IFNγ stimulation for 24, 48,
and 72 h. Hematopoietic genes (i), IFNγ-induced genes (ii), IRF genes (iii). (iv) Changes in ICSBP levels, confirmed by quantitative PCR;
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236 E. Dobbin et al.ICSBP, and STAT2 were induced by IFNγ throughout the
differentiation process (Fig. 6D), whereas only a slight increase
in SOCS1 and decrease in HDAC9 were observed (Fig. 6E, ii).
Surprisingly although ICSBP was highly up-regulated by IFNγ
treatment during differentiation (Fig. 6D, iii), Egr1 and 2, genes
reported to be directly regulated by ICSBP, were down-
regulated (Fig. 6E, i). Egr1 and 2 are highly expressed in early
myeloid progenitors and this down-regulation during differen-
tiation may reflect the fact that IFNγ enhanced the differen-
tiation process. Id1 levels were also lower in the IFNγ-treatedsamples, suggesting active negative regulation of the IFNγ
response by endogenous Tel (Fig. 6E, ii).Discussion
In this study we conducted a detailed proteomic screen to
identify key initiating steps that can lead to MPN caused by
Tel/PDGFRβ. The data indicate that expression of this
oncoprotein in stem cell models has a profound effect on
237Leukaemic oncogene Tel/PDGFRβ in stem cellsproteins involved in various cellular functions. These included
alterations in expression of proteins that can modulate the
motility, metabolism, transcription, protein biosynthesis,
oxidative phosphorylation, and signal transduction. Of most
interest from this expression dataset was concomitant up-
regulation of several proteins induced by IFNγ. These proteins
were characterised as either being involved in IFNγ signaling
(IFNγ GTPase, GBP1, GBP2, IFN-induced transmembrane
protein 3) and transcription (histone acetylase CBP/p300
interacting transactivator 2) or to be altered as a direct result
of the IFNγ response (MECL-1 and PA28α). To our knowledge
this is the first indication of the ability of Tel/PDGFRβ toFigure 6 IFNγ induces IFNγ response genes through STAT1 up-regulat
FDCP-Mix cells induced to undergo eithermonocytic or neutrophilic diffe
4, and 7. Late progenitors indicate metamyelocytes, myelocytes, and p
was b10% in all cases with 250 cells counted per condition for each expe
(ii) and suppresses neutrophilic (iii) differentiation; * Pb0.05 by pai
monocytic, and granulocytic differentiation genes following IFNγ tre
immunoblotted using antibodies against STAT1, pSTAT1, ICSBP with G
transcription factors involved in the IFN response (i and ii). (iii) Changes i
by paired Students t test, n=3. (E) RT-PCR of genes regulated by ICSB
Representative gel images are shown for each gene, n=3.induce IFNγ response proteins, highlighting the power of
hypothesis generation systematic proteome analyses.
The IFNγ response is mediated through STAT1 activation,
enabling it to bind to GAS sites in the promoter of target
genes, especially the IRF family of transcription factors
(Schindler and Plumlee, 2008). Our data clearly demonstrate
that IFNγ can up-regulate and activate STAT1 in ES and FDCP-
Mix cells and that Tel/PDGFRβ is able to cause this
independently of IFNγ stimulation. In addition ICSBP was
markedly up-regulated in response to Tel/PDGFRβ and IFNγ
with a modest increase in IRF-9. IRF-4 was also up-regulated
in the ES cells whereas IRF-1 was up-regulated in the FDCP-ion and activation duringmyeloid differentiation. Effects of IFNγ on
rentiation over 7 days. (A) (i)Morphologywas determinedonDays 0,
romonocytes. Results shown are the mean of three experiments; SE
riment. Additional graphs indicating that IFNγ increases monocytic
red Students t test, n=3. (B) RT-PCR analysis of hematopoietic,
atment, n=3. (C) Representative gel images of protein extracts
APDH used as a loading control, n=3. (D) Analysis of downstream
n ICSBP levels, confirmed by quantitative PCR; * Pb0.05, # Pb0.005
P (i) and involved in negative regulation of the IFNγ response (ii).
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238 E. Dobbin et al.Mix cells in response to both Tel/PDGFRβ and IFNγ,
suggesting that IFNγ mediates different responses in
pluripotent and myeloid stem cells. Interestingly IRF-1 can
suppress transcription in response to IFNγ (Mamane et al.,
1999). IRF-4 acts as a natural antagonist of IRF-1 transactiva-
tion, which may be a potential mechanism enhancing the
Tel/PDGFRβ-mediated IFNγ response in more primitive stem
cells. Since class 1 IFNs (IFNα/β) induce transcription
through STAT1:STAT2:IRF-9 heterotrimers, we also investi-
gated STAT2 levels. Our results indicate that Tel/PDGFRβ
and IFNγ up-regulate STAT2, suggesting that IFNγ signaling
may also prime cells to respond to class 1 IFNs.
Initially STAT1 and IFNγ signaling were thought to protect
against tumor development, with STAT1-/- and IFNγ-/- mice
having a higher incidence of tumor formation. (Lesinski
et al., 2003; Kaplan et al., 1998). In contrast emerging
evidence in mouse models suggests that STAT1 expression
plays an important role in the development of leukemia.
Expression of leukemic oncogenes in STAT1-/- mice gives rise
to emerging leukemic cells that are killed by NK cells during
immunological survelliance due to the low abundance of
MHC1 (Kovacic et al., 2006). In our Tel/PDGFRβ models we
show that Tel/PDGFRβ dramatically up-regulates and acti-
vates STAT1, leading to enhanced transcription of ICSBP, akey transcription factor involved in monocytic and eosino-
philic development (Holtschke et al., 1996; Milanovic et al.,
2008). Interestingly ICSBP-/-mice show suppressed myeloid/
eosinophilic differentiation and enhanced granulocytic dif-
ferentiation. This ultimately leads to the development of a
MPN which closely resembles chronic myeloid leukemia
(CML) in humans (Holtschke et al., 1996; Milanovic et al.,
2008). The study by Cain et al., determined that STAT1 had a
slightly immunosuppressive role in Tel/PDGFRβ mouse
models of MPN, with STAT1-/- mice having a shorter latency
to disease development (Cain et al., 2007). Although the
STAT1-/- mice developed rapidly fatal MPN in response to
Tel/PDGFRβ with leukocytosis, extramedullary hematopoi-
esis, and splenomegaly, the MPN was not characterised at
the cellular level (Cain et al., 2007). It would be interesting
to determine whether these mice develop a MPN more akin
to CML rather than the myelomonocytic leukemia normally
associated with Tel/PDGFRβ due to lack of STAT1 resulting in
suppressed ICSBP levels.
Myeloid differentiation involves a complex network of
transcription factors which interact with each other to
control specific lineages. The ability of ICSBP to interact with
other transcriptional regulators such as the Ets family of
transcription factors and CBP/p300 requires phosphorylation
239Leukaemic oncogene Tel/PDGFRβ in stem cellsvia the COP9/signalosome (CSN) complex (Cohen et al.,
2000). Both the CSN complex and the CBP/p300 transacti-
vator 2 were up-regulated by Tel/PDGFRβ in the proteomic
screen, suggesting that Tel/PDGFRβ also enhances proteins
involved in potentiating ICSBP transcription. ICSBP-interacting
partners include PU.1, transcription factors involved in
eosinophilic differentiation (GATA1, GATA2, C/EBPε), and
specific ICSBP target genes involved in monocytic develop-
ment (Egr1, Egr2, PML, andNF1) and regulating apoptosis (Bcl-
2). No expression of PU.1 was observed following Tel/PDGFRβ
expression, consistent with findings showing that PU.1 is more
important for terminal differentiation than the early stages of
myelopoiesis (Mueller et al., 2002; Metcalf et al., 2006). Tel/
PDGFRβ up-regulated GATA1 and 2, VDR and C/EBPε, in ES
cells, key transcriptional regulators of eosinophilic (GATA1 and
2) (Dobbin et al., 2008; Yu et al., 2002; Hirasawa et al., 2002)
andmonocytic commitment (VDR andC/EBPε) (Williams et al.,
1998). During myelomonocytic differentiation, Tel/PDGFRβ
increased transcription of VDR and C/EBPε, with more evident
alterations observed during neutrophilic differentiation with
GATA1 and VDR up-regulated whereas GFi and G-CSF-R were
down-regulated. These findings indicate that the oncogene
can exert its effects to bias myelomonocytic differentiation
even in the presence of cytokines which promote neutrophilic
granulocyte development. In addition Tel/PDGFRβ up-regu-
lated Egr1 and Egr2, genes directly controlled by ICSBP and
implicated in early commitment along the monocytic lineage
(Nguyen et al., 1993). Of the genes which ICSBP directly
regulates, only NF1 transcription was slightly down-regulated
following Tel/PDGFRβ expression, consistent with reports of
NF1 deficiencies in the pathogenesis of other malignant
myeloid disorders (Lu et al., 2003). Our results indicate that
Tel/PDGFRβ has the ability to alter the transcriptional factor
network to bias differentiation toward the monocytic and
eosinophilic lineages through increased transcription of IRF-1,
IRF-4, ICSBP, IRF-9, GATA1, GATA2, VDR, C/EBPε, Egr1, Egr2
and reduced transcription of NF1. Surprisingly although
transcription factors involved in myelomonocytic differentia-
tion were high in the IFNγ-treated samples. GATA 1 and 2,
VDR, and C/EBPε levels were lower than in the control
samples, potentially reflecting the increased rate of differen-
tiation observedwith IFNγ treatment. In otherwords there are
a plethora of changes mediated by Tel/PDGFRβ registered on
this pathway that can have a concatenated effect to disrupt
development.
Normally the IFNγ signaling cascade would be down-
modulated (i.e., switched off) within 1–2 h of IFNγ stimu-
lation. This is mediated by two distinct classes of molecules,
SOCS and PIAS. No change in PIAS levels were observed,
although Tel/PDGFRβ did result in the up-regulation of
SOCS1 and SOCS3 transcription. However previous studies
indicate that Tel/PDGFRβ directly binds and activates STATs
in a JAK-independent fashion (Wilbanks et al., 2000);
therefore, induction of SOCS1 and SOCS3 is unlikely to
down-regulate STAT activation in response to Tel/PDGFRβ.
ICSBP can also suppress the IFNγ-induced response through
interactions with endogenous Tel and recruitment of HDACs
(Kuwata et al., 2002). Kinetic studies demonstrate that
binding of IRF family members to ISRE elements occurs
quicker than recruitment of the Tel/HDAC3/ICSBP complex,
indicating that activation of transcription occurs prior to Tel-
mediated repression (Kuwata et al., 2002). Our resultsindicate that Tel/PDGFRβ did increase HDAC3 transcription,
but had no effects on Tel transcription. These results again
indicate that following Tel/PDGFRβ-mediated IFNγ signal-
ing, negative regulation of the response was induced in the
cells. The activity of Tel is regulated at multiple levels with
Tel cellular localization tightly regulated by the p38, ERK,
and Src kinases, signaling pathways activated by Tel/PDGFRβ
(Tomasson et al., 2000; Wheadon and Welham, 2003), which
can all phosphorylate Tel, resulting in Tel losing its DNA
binding and repression ability (Maki et al., 2004; Arai et al.,
2002; Hanson et al., 2008). Tel mRNA encodes two proteins
of 57 and 50 kDa, with the smaller form of Tel shown to have
much stronger repressive effects due to the lack of a
sumoylation site (Poirel et al., 1997). Surprisingly, Tel/
PDGFRβ up-regulated the smaller 50-kDa Tel protein, which
was mainly located in the cytoplasm following Tel/PDGFRβ
expression. In order to determine Tel's repressional activity,
we investigated one of its target genes Id1 (Martinez and
Golub, 2000). Following Tel/PDGFRβ induction, Id1 tran-
scription was markedly up-regulated, indicating that endog-
enous Tel is unable to repress transcription. Id1 transcription
is positively regulated by Egr1 (Tournay and Benezra, 1996),
which may explain why Id1 is so highly up-regulated following
Tel/PDGFRβ expression. Recently Id1 has been shown to be a
common downstream target in other hematological disorders
involving several other activated tyrosine kinases, including
Tel/PDGFRβ, with up-regulation linked to promoting cell
proliferation (Tam et al., 2008). In view of the fact that Tel is
lost in childhood B-precursor acute lymphoblastic leukemia
(Kempski and Sturt, 2000), AML, and MDS (Akagi et al., 2008),
sustained IFN signaling could be a contributing factor to the
development of other leukemias.Conclusions
Overall our findings indicate that IFNγ has a potent effect on
both primitive pluripotent stem cells and myeloid progenitors
and plays an important role in myeloid commitment. Patients
with the Tel/PDGFRβ translocation potentially develop MPN
with associated eosinophilia due to aberrant IFN signaling and
deregulation of the negative feedback loops necessary to
switch off this response (summarized in Fig. 7). This is
mediated through STAT1 up-regulating IRF-1, IRF-4, ICSBP,
IRF-9, and STAT2, leading to the transcription of additional
transcription factors which are major regulators involved in
myelomonocytic and eosinophilic commitment.Materials and methods
Cell culture
E14tg2a murine ES cells and BaF3 cells expressing the Tet-
sensitive transactivator, tTA, and Tel/PDGFRβ transfectants
were cultured as previously described (Wheadon and Wel-
ham, 2003; Dobbin et al., 2008). For induction of oncogene
expression, Tel/PDGFRβ clones were washed three times
with phosphate-buffered saline (PBS) and incubated in the
presence of 500 ng/mL Tet to prevent the expression of Tel/
PDGFRβ, or no Tet to induce the expression of Tel/PDGFRβ
for 24, 48, or 72 h. For the inhibitor studies cells were
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Figure 7 Schematic diagram illustrating the alterations in IFNγ signaling induced by the oncogene Tel/PDGFRβ.
240 E. Dobbin et al.inhibited with 1 μM imatinib mesylate (Novartis, Horsham,
UK), 3 μM PDGFRβ inhibitor III (Calbiochem, Nottingham,
UK), 10 or 25 μM of the MEK inhibitor U0126 (Sigma, Dorset,
UK), and the p38 inhibitor SB202190 (Calbiochem), as
indicated. Parental E14tg2a ES cells and FDCP-Mix cells
were cultured as previously described (Dobbin et al., 2008;
Unwin et al., 2005) with and without 100 ng/mL recombinant
IFNγ supplementation (PeproTech, London, UK) for 24, 48,
and 72 h.
Myeloid differentiation
For differentiation induction, FDCP-Mix cells were washed
three times in PBS and cultured in IMDM with 20% FBS
(Invitrogen, Paisley, UK) and cytokines to induce monocytic
(0.1 ng/mL IL-3, 10 ng/mL GM-CSF, and 5 ng/mL M-CSF) or
neutrophilic (0.1 ng/mL IL-3, 10 ng/mL GM-CSF, and 10 ng/
mL G-CSF) (PeproTech) commitment with and without
100 ng/mL IFNγ as indicated over 7 days. Cytospins were
prepared following 0, 4, and 7 days of differentiation, and
cells were fixed and stained using May-Grünwald-Giemsa,
with morphology determined by light microscopy.
iTRAQ labeling
ES cell transfectants (1×107) were incubated with and
without 500 ng/mL Tet for 24 h to repress or induce Tel/PDGFRβ. Cells were lysed in 200 μL, 0.5 M triethylammonium
bicarbonate (Sigma)+0.05% (w/v) sodium dodecyl sulfate,
on ice for 20 min. The lysate was centrifuged at 10,000 g for
20 min at 4 °C, supernatant removed, and protein quantified
using Bradford reagent (Bio-Rad, Hertfordshire, UK). Protein
was trypsinised and isobarically tagged as previously de-
scribed (Pierce et al., 2008; Unwin et al., 2005).Peptide fractionation and mass spectrometry
Pooled peptide samples were fractionated off-line using an
SCX Polysulfoethyl A cation-exchange column on an Agilent
1100 series instrument. The gradient was formed at 250 μL/
min using, initially, 10 mM KH2PO4, 20% ACN, pH 2.7, with KCl
concentration increasing from zero to 250 mM over 45 min,
and then 250 to 500 mM over 10 min followed by 1 M for
5 min. Fractions were collected every 2 min. Fractions were
concentrated by drying and resuspended in 110 μL of 2%
acetonitrile/0.1% formic acid (v/v) and 60-μL aliquots were
analysed by liquid chromatography/MS on a QSTAR XL MS
(Applied Biosystems) as described previously (Pierce et al.,
2008; Unwin et al., 2005). Data were processed by
performing a “Thorough” search against mouse protein
cod ing sequence reg ion CDS database (mou-
se_KBMS5_0_20050302, 115,660 entries) using the Paragon
algorithm within ProteinPilot v1.1 software with trypsin as
the digest agent. Only peptides with a minimum confidence
241Leukaemic oncogene Tel/PDGFRβ in stem cellsscore of 70% were included in the final dataset; this allowed
only the highest quality MS/MS spectra to be used for protein
identification and therefore relative quantification. A
minimum of three spectra was required to identify and
relatively quantify a protein. iTRAQ ratios greater than or
equal to 1.2 or less than 0.8 with a P value less than 0.05
were flagged as being differentially expressed. For protein
relative quantification, only MS/MS spectra which were
unique to a particular protein and where the sum of the
signal-to-noise ratio for all of the peak pairs is N9 were used
for quantification (default software settings). For each
protein ratio a P value was generated by the ProteinPilot
v1.1 software to assess whether the protein was significantly
differentially expressed. P value determination was calcu-
lated using the Student t factor by dividing (weighted
average of log ratios – log bias) by the weighted standard
deviation, allowing determination of the P value, with n–1
degrees of freedom, where n is the number of peptides
contributing to protein relative quantification. The protein
identification data search was performed against a concat-
enated database containing both forward and reverse
sequences (231 320 entries), enabling an estimation of the
false discovery rate to be obtained.
Nuclear extracts
ES cells (1×107) were cultured with or without Tet for 48 h to
induce the expression of Tel/PDGFRβ. Cells were harvested
and washed three times with ice-cold PBS prior to protein
extraction. Cytoplasmic and nuclear extracts were prepared
using a Nuclear Extraction Kit (Millipore, Hertfordshire, UK) as
described in the manufacturer's instructions. Protein concen-
trations were determined using a Bio-Rad protein assay kit.
Immunoblotting
For immunoblotting, 20 μg of cell lysates was fractionated by
SDS-PAGE and blotted onto nitrocellulose. Primary antibodies
were used at the following dilutions: 0.1 μg/mL anti-phospho-
tyrosine 4G10 (Upstate Biotechnology, Hertfordshire, UK, 05-
321); 0.5 μg/mL PDGFRβ antibody, which recognizes Tel/
PDGFRβ (Cell Signaling Technology, Hertfordshire, UK, CST-
3162), 1:1000 anti-phospho ERK (CST-9101), anti-phospho p38
(CST-9212), anti-p38 (CST-9212), anti-STAT1 (CST-9172), anti-
phospho STAT1 Tyr701 (CST-9171), anti-phospho STAT1 Ser727
(CST-9177), GAPDH (CST-2118), 1:2000 anti-SHP-2 (Santa Cruz
Biotechnology Inc., London, UK, sc-293), anti-ERK (sc-93),
1:500 for antibodies against Tel (sc-8546), and ICSBP (sc-6058).
Secondary antibodies, conjugated to horseradish peroxidase
(Dako, Cambridgeshire, UK), were used at 1:10000 dilution and
blots developed using enhanced chemiluminescence (Thermo
Fisher Scientific, Leicestershire, UK).
RT semiquantitative and quantitative PCR analyses
Total RNA was prepared using RNAeasy Plus extraction kit
(Qiagen, West Sussex, UK) and concentrations were mea-
sured using a Nanodrop Spectrophotometer (LabTech). RNA
(1 μg) was reverse-transcribed using Superscript reverse
transcriptase and oligo(dT) primers (Invitrogen). Gene-
specific primers (Supplementary Table 1) were designedwith a predicted annealing temperature of 60 °C and
incorporated≥1 intron:exon boundary. Consistent expres-
sion levels for each gene at a cycle number below saturation
were determined before semiquantitative analysis of target
genes was performed. PCR was performed using 2 μL of cDNA
under standard conditions and 24–30 cycles. PCR products
(180–280 bp) were separated and visualized by electropho-
resis. Two housekeeping genes (GusB and TBP) with medium/
low level expression were used as endogenous references for
the quantification of target genes. Relative quantification
was carried out on a 7900HT Fast Real-Time PCR System
(Applied Biosystems). Ten-microliter total volume reactions
were performed using 1 μL cDNA in 384 plate format as per
the manufacturer's instructions. A single run contained four
log dilutions of each cDNA sample in triplicate. A final
melting curve analysis (65–95 °C, plate read/0.2 °C, hold
2 s) was performed as an indicator of amplicon specificity.
Data were quantified using RQ Manager analysis software.
For normalization, expression of mouse TBP was determined
in parallel as an endogenous control. Relative gene expres-
sion was calculated using the 2-ΔΔCT method. The RQ ratio
(arbitrary units) between target gene and endogenous
control was plotted as a measure of mRNA gene expression.
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